---
document_datetime: 2023-09-21 17:45:59
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/prevenar-epar-procedural-steps-taken-authorisation_en.pdf
document_name: prevenar-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5390009
conversion_datetime: 2025-12-18 21:42:11.725542
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

•

•

The applicant Wyeth Lederle Vaccines S.A., Belgium submitted on 12 October 1999 an application for  Marketing  Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products (EMEA)  for  Prevenar,  through  the  centralised  procedure.  After  agreement  by  the  CPMP  on  1820 May 1999, this medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993 as amended. The Rapporteur and Co-Rapporteur appointed by the CPMP were: Rapporteur: Daniel Brasseur Co-Rapporteur: Per Nilsson Scientific Advice: The applicant did not seek scientific advice at the CPMP. Licensing status: Prevenar has been given a Marketing Authorisation in USA on 17 February 2000. 2. Steps taken for the assessment of the product · The procedure started on 19 November 1999. · The Rapporteur's first Assessment Report was circulated to all CPMP  members  on 28 January 2000.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP members on 4 February 2000. · The  BWP  during  its  meeting  of  7-8  March  2000,  adopted  the  BWP  recommendation  to  be transmitted to the CPMP for endorsement. · During  the  meeting  on  14-17  March  2000  the  CPMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 17 March 2000. · The  company  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on 17 May 2000. · The favourable summary report of the inspection carried out at the manufacturing site between 19-20 April 2000 of the Wyeth Lederle Vaccines, 401 North Middletown Road, NY 109651299, Pearl River, USA was issued by the Medicines Control Agency, Market Towers, 1 Nine Elms Lane, London SW8 5 NQ, and United Kingdom on 13 June 2000. · The  EMEA  circulated  the  Rapporteur's  and  Co-Rapporteur's  joint  assessment  report  on  the company's responses to the List of Questions to all CPMP members on 3 July 2000. The  BWP  during  its  meeting  of  20-21  July  2000,  adopted  the  BWP  recommendation  to  be transmitted to the CPMP for endorsement. The CPMP in its meeting of 25-27 July 2000 adopted the BWP recommendation and the list of outstanding issues and agreed that an oral explanation would be necessary to address them. · On 27 July 2000 the company requested a 'stop-of-the-clock' in order to prepare for the oral explanation.  The  revised  list  of  outstanding  questions  to  be  addressed  at  the  oral  explanation was sent to the company on 27 July 2000. Medicinal product no longer authorised

- The company provided supplementary written information addressing the outstanding questions to the CPMP members on 23 August 2000.
- The BWP during its meeting of 12-13 September 2000, adopted the BWP recommendation to be transmitted to the CPMP for endorsement.

<div style=\"page-break-after: always\"></div>

- The fabourable summary report of the inspection carried out at the manufacturing site between 17-18 April 2000 of Wyeth Lederle Vaccines, 4300 Oak Park, NC 27330, Sanford, USA, was issued by the Medicines Control Agency, Market Towers, 1 Nine Elms Lane, London SW8 5 NQ, United Kingdom on 14 September 2000.
- During the CPMP meeting on 20 September 2000, outstanding issues were addressed by the applicant during a hearing before the CPMP.

· The EMEA circulated the Rapporteur's and Co-Rapporteur's joint assessment report following the applicants hearing to all CPMP members on 4 October 2000. · The  company,  Wyeth  Lederle  Vaccines  S.A.,  provided  on  13  October  2000,  a  letter  of undertaking on the follow-up measures to be fulfilled as requested by the CPMP. · During the meeting on 17-19 October 2000 the CPMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation to Prevenar on 19 October 2000. Medicinal product no longer authorised